ResearcherUNSW SydneyActive in the last 2 years

Sarah E. Hancock

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7541-8901; OpenAlex author ID A5088807173. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 2

Targeting de novo lipogenesis improves gemcitabine efficacy in pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2024.12.18.628624 ↗
Snail-Overexpression Induces Epithelial-mesenchymal Transition and Metabolic Reprogramming in Human Pancreatic Ductal Adenocarcinoma and Non-tumorigenic Ductal… First author DOI 10.3390/jcm8060822 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Nigel A. Turner · 2 shared papers, 2019–2024 · strength 0.28
- Paper Targeting de novo lipogenesis improves gemcitabine efficacy in pancreatic ductal adenocarcinoma DOI 10.1101/2024.12.18.628624 ↗
- Paper Snail-Overexpression Induces Epithelial-mesenchymal Transition and Metabolic Reprogramming in Human Pancreatic Ductal A… DOI 10.3390/jcm8060822 ↗
Menghan Liu · 1 shared paper, 2019 · strength 0.10
- Paper Snail-Overexpression Induces Epithelial-mesenchymal Transition and Metabolic Reprogramming in Human Pancreatic Ductal A… DOI 10.3390/jcm8060822 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.